Anavex Life Sciences EBIT

Anavex Life Sciences (AVXL) currently reports a EBIT of $-30M as of December 2025. That compares with $-81M in the prior-year period — up 63.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Anavex Life Sciences's EBIT history and peer comparisons.

Anavex Life Sciences's EBIT increased from $-81M to $-30M — a 63.2% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Anavex Life Sciences's EBIT of $-30M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Anavex Life Sciences reported $-30M in EBIT as of December 2025. That compares with $-81M in the prior-year period — up 63.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Anavex Life Sciences, and consider following AVXL for alerts when major investors trade the stock.